Vertaling van "demonstrated the efficacy and safety " (Nederlands → Frans) :

Clinical trials demonstrated the efficacy and safety of FTY720, with participants showing reduced relapses and delayed disease progression.
Des essais cliniques ont démontré l’efficacité et l’innocuité de FTY720 qui provoque une diminution des rechutes et un ralentissement de la progression de la maladie chez les participants.

45 2001 literature review ------- ------------- For intermediate risk patients, no prospective RCT demonstrates the efficacy of non invasive stress testing or subsequent revascularization for preventing perioperative cardiac events.
47 2001 literature review ------- ------------- For intermediate risk patients, no prospective RCT demonstrates the efficacy of non invasive stress testing or subsequent revascularization for preventing perioperative cardiac events.

SOM230 (pasireotide) demonstrated significant efficacy in a Phase III trial in reducing the level of urinary free cortisol (UFC) in patients suffering from Cushing’s disease, a potentially fatal and debilitating hormonal disorder.
réduction du taux de cortisol libre urinaire (CLU) chez les patients souffrant de la maladie de Cushing, une maladie hormonale potentiellement mortelle et invalidante.

HGR 8838: Peptide Receptor Radionuclide Therapy “In this advisory report, the Superior Health Council provides a risk assessment (efficacy, toxicity, safety and radioprotection) for Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium-177 and Yttrium-90 for patients diagnosed with gastroenteropancreatic neuroendocrine tumours.
CSS 8838: Peptide Receptor Radionuclide Therapy “In this advisory report, the Superior Health Council provides a risk assessment (efficacy, toxicity, safety and radioprotection) for Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium-177 and Yttrium-90 for patients diagnosed with gastroenteropancreatic neuroendocrine tumours.

BMJ 2004; 329:1317 Lee C, Straus W, Balshaw R et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis.
BMJ 2004; 329:1317. Lee C, Straus W, Balshaw R et al. A comparison of the efficacy and safety of nonsteroidal antiinflammatory agents versus acetaminophen in the treatment of osteoarthritis: a meta-analysis.

Reinforcing its efficacy and safety profile, new long-term data from a pivotal fracture trial show Aclasta preserved bone mass in patients who received annual infusions for six years and the risk of new morphometric spine fractures was reduced by 52% when measured as a secondary endpoint compared to those who stopped treatment at three years.
Renforçant son profil d’efficacité et d’innocuité, de nouveaux résultats provenant d’un essai pivot de long terme sur les fractures montrent que Reclast/Aclasta conserve la masse osseuse de malades qui ont reçu une perfusion annuelle pendant six ans. En outre, le risque de nouvelles fractures morphométriques de la colonne vertébrale, mesuré en tant que critère secondaire, a été réduit de 52% par rapport aux malades qui ont arrêté le traitement au bout de trois ans.

A recent review of data from previous Phase III trials confirmed the known efficacy and safety profile of the drug.
Une revue récente des résultats d’essais de phase II antérieurs a confirmé le profil connu d’efficacité et d’innocuité de ce médicament.

Key drivers are clinical data demonstrating its prolonged efficacy in lowering blood pressure for more than 24 hours, and superiority in clinical trials over ramipril, a leading ACE inhibitor (an older class of high blood pressure medicines).
Les facteurs-clés de cette progression sont des données cliniques faisant état de sa capacité à réduire la pression sanguine pendant plus de 24 heures et de sa supériorité, lors d’essais cliniques, sur le ramipril, un inhibiteur important de l’IEC (une catégorie plus ancienne de médicaments hypotenseurs).

Tekturna/Rasilez (USD 290 million, +104% lc), the first in a new class of medicines known as direct renin inhibitors to treat high blood pressure, has been growing consistently since its launch in 2007 based on positive clinical data demonstrating its prolonged efficacy in lowering blood pressure for more than 24 hours and superiority in clinical trials over ramipril, a leading ACE inhibitor.
Rasilez/Tekturna (USD 290 millions, +104% en m. l.), est le premier d’une nouvelle classe de médicaments, les inhibiteurs directs de la rénine, traitant l’hypertension.

Initial data from the Phase III program with over 4,200 patients in 30 countries suggest a good efficacy/safety profile.
Les premiers résultats fournis par un programme de phase III impliquant plus de 4 200 patients dans 30 pays indiquent un bon profil efficacité/innocuité.